The relevant ECHA guidance document ("How to report weight of evidence") is focusing mainly on the technical issues of reporting a WoE approach in the registration dossier.
For the WoE approach, the REACH guidance document "How to report weight of evidence", published by the ECHA [57] was consulted.
They are less effective (3.5% of initial body weight) in the reported weight decrease of their patients.
While short-term studies have described similar findings in children [ 45, 46], to our knowledge, only one intermediate-term placebo controlled pediatric trial of an SSRI reported weight changes.
He reported weight loss of 10 kg over the previous 45 days.
To reduce any recall error of reported weight comments, a shorter time frame of the past 30 days was used.
Patients with high cholesterol levels accounted for 74.1%% of those who reported weight gain, 55.7 % of those who reported weight loss, and 53.8 % of those who reported no weight change (p < 0.05).
In addition, the owner reported weight loss over a period of several months.
This high consent rate may be due to the use of the touchscreen computer which could have provided participants with a more private way of reporting weight and height.
It was not possible to determine whether those studies reporting weight were a biased sample of all smoking cessation trials, although we found no evidence of bias on the funnel plot.
We limited eligible births for our study to singleton births with known birth order, known maternal race, known maternal education, known marital status, known maternal age, known birth weight, and a reported gestational age of up to 44 weeks.
